Perx Health Seed
π¦ Potential exit path:
M&A

Select partners: AIA, QBE, Roche, AstraZeneca, Australia's national healthcare system.
Funding π°
Total $2.2M
Last round π October 13, 2021.
Select investors AirTree Ventures, ANDHealth, Giant Leap Fund
Key people π§βπ€βπ§
- Hugo Rourke - Co-founder & CEO
- Scott Taylor - Co-founder & CEO
- Ernesto Vinagre - VP of Sales & Partnerships
- Kelsey (Thomas) Kohl - VP of Sales & Partnerships
- Clare Thompson - Head of People & Culture
- Camus Ulloa-Jonsson - Head Of Engineering & Technology
Highlights β
- Even though it's a relatively new company, Perx has already managed to partner with some of the world's largest companies.
- The company's solution has been proven to work in multiple peer-reviewed publications, including gold-standard randomized control trial with University of Sydney. Perx has an average daily engagement of 4.4 sessions and an average treatment plan adherence of over 95%. π
- The company's plans include expansion to the U.S. and to that end, Perx has hired Sales and Marketing professionals from leading U.S. digital health companies like Omada, Physera, Propeller, Diagnostic Robotics, and Crossover Health. π
- Perx is in a huge market, which according to CDC, includes over 150 million Americans who live with a chronic condition. π
- "The Perx team has solved the hardest problem in digital health, maintaining the attention of the most complex and most vulnerable patients. The opportunities are now endless for how they could use that attention to help payers and providers transition care from reactive and sporadic to preventative and continuous." - Jackie Vullinghs, Partner at AirTree Ventures. π
Last update: December 28, 2021
Disclaimer: We can not guarantee that the information on this page is 100% correct. more